BlackRock reveals Vesta Real Estate (NYSE: VTMX) share stake

Vesta reported Q3 revenue up 9.9% to $79.6M, raising 2026 revenue growth outlook to 11.5-12.5%. Occupancy rose to 93.9%, with 2.3M sq ft of leases signed. Adjusted NOI up 10.4% to $72.9M, EBITDA up 9.2% to $65.2M. Cash earnings per share fell 9.2% due to higher interest costs.

Corporacion Inmobiliaria Vesta (VTMX) reported Q3 revenue of $79.6M, up 9.9% YoY. The company raised its 2026 revenue growth forecast to 11.5-12.5%. Management highlighted demand from AI, electronics, and e-commerce sectors, with Mercado Libre as its largest tenant. Vesta acquired a Mexico City land parcel and plans to focus on urban infill sites. Adjusted NOI and EBITDA margins improved, and credit ratings were upgraded by S&P and Fitch.

Vesta Real Estate Corporation, S.A.B. de C.V. (VTMX) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Q3 2026 EARNINGS RESULTS Conference Call Friday, October 23, 2026 9:00 a.m. (Mexico City Time) 11:00 a.m. (Eastern Time) To participate in the conference call please connect via webcast or by dialing: International Toll-Free: +1 (833) 461-5787 International Toll: +1

SFL Corporation (NYSE: SFL) announced plans to acquire three vessels: two 8,800 TEU container vessels and one 93,000 cbm dual-fuel ammonia carrier. The acquisitions, costing approximately $333 million, include long-term charters with options for extension and purchase. According to the company, these charters will add significant revenue.

Cerebras Systems (CBRS) shares rose 10% and Oracle (ORCL) gained 4% on Oct. 27 after Oracle announced plans to offer Cerebras' AI inference on its cloud starting in 2027. The deal aims to provide customers with more AI chip options. Analysts estimate Cerebras' 2027 revenue at $2.95 billion, though no deal value was disclosed. Cerebras trades at roughly half its average forward price/sales multiple since its IPO.

ProKidney (NASDAQ:PROK) expects Phase III readout for rilparencel in Q2 2027, with enrollment surpassing 500. The therapy showed a 78% slower annual eGFR decline in Phase II. ProKidney aims to complement existing CKD treatments, with manufacturing efficiency improvements planned. Safety data aligns with prior trials, focusing on kidney biopsy-related events.